Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec 19;14(6):e0177723.
doi: 10.1128/mbio.01777-23. Epub 2023 Nov 8.

Factors associated with mortality among hospitalized patients with COVID-19 disease treated with convalescent plasma

Armando M Perichon  1 , Andrea Acosta  2 , Liliana Di Tulio  2 , Maria José Munuce  3 , Stella Pezzotto  4   5 , Oscar Bottasso  4   5 , Esteban C Nannini  4   6
Affiliations

Factors associated with mortality among hospitalized patients with COVID-19 disease treated with convalescent plasma

Armando M Perichon et al. mBio. .

Abstract

The use of convalescent plasma (CP) could be an option for patients with severe COVID-19, especially in poor-resource countries where direct antiviral drugs are not commercially available. Currently, the U.S. Food and Drug Administration limits the CP administration for outpatients and inpatients with COVID-19 who are immunocompromised and only if high levels of anti-SARS-CoV-2 antibodies are confirmed in the CP unit. Although most of the randomized clinical trials failed to show a clear-cut benefit of CP in hospitalized patients with severe COVID-19, other studies have shown that if given early in the course of the disease, it might be a useful therapeutic option. In this retrospective study, we demonstrated that early treatment (within 3 days of hospitalization) was significantly associated with reduced 28-day mortality compared with those patients treated beyond day 3. The results from our study add up to the scientific evidence on the use of CP as a relatively safe, cheap, and possibly effective therapy in certain patients suffering from severe SARS-CoV-2 infection.

Keywords: COVID-19; SARS-CoV-2; convalescent plasma; immunotherapy; pneumonia; transfusion.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Fig 1
Fig 1
Proportion of patients in each of the simplified WHO scores at baseline and at day 28 (n = 480). Score 1: discharged; score 2: hospitalized without supplemental oxygen; score 3: hospitalized with supplemental oxygen; score 4: invasive mechanical ventilation, ECMO or vasopressors; score 5: death.
Fig 2
Fig 2
Odds ratio (logarithmic scale) of factors associated with mortality at day 28 after CP administration.
See this image and copyright information in PMC

Comment in

References

    1. Maiztegui JI, Fernandez NJ, de Damilano AJ. 1979. Efficacy of immune plasma in treatment of argentine haemorrhagic fever and association between treatment and a late neurological syndrome. Lancet 2:1216–1217. doi:10.1016/s0140-6736(79)92335-3 - DOI - PubMed
    1. Enria DA, Briggiler AM, Fernandez NJ, Levis SC, Maiztegui JI. 1984. Importance of dose of neutralising antibodies in treatment of argentine haemorrhagic fever with immune plasma. Lancet 2:255–256. doi:10.1016/s0140-6736(84)90299-x - DOI - PubMed
    1. Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, Zhou M, Chen L, Meng S, Hu Y, et al. . 2020. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A 117:9490–9496. doi:10.1073/pnas.2004168117 - DOI - PMC - PubMed
    1. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, Wang F, Li D, Yang M, Xing L, Wei J, Xiao H, Yang Y, Qu J, Qing L, Chen L, Xu Z, Peng L, Li Y, Zheng H, Chen F, Huang K, Jiang Y, Liu D, Zhang Z, Liu Y, Liu L. 2020. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA 323:1582–1589. doi:10.1001/jama.2020.4783 - DOI - PMC - PubMed
    1. Simonovich VA, Burgos Pratx LD, Scibona P, Beruto MV, Vallone MG, Vázquez C, Savoy N, Giunta DH, Pérez LG, Sánchez MDL, et al. , PlasmAr Study Group . 2021. A randomized trial of convalescent plasma in COVID-19 severe pneumonia. N Engl J Med 384:619–629. doi:10.1056/NEJMoa2031304 - DOI - PMC - PubMed

Substances